Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 7

1.

Mitochondrial impairment in patients with Parkinson disease with the G2019S mutation in LRRK2.

Mortiboys H, Johansen KK, Aasly JO, Bandmann O.

Neurology. 2010 Nov 30;75(22):2017-20. doi: 10.1212/WNL.0b013e3181ff9685.

PMID:
21115957
2.

The LRRK2 G2019S mutation as the cause of Parkinson's disease in Ashkenazi Jews.

Thaler A, Ash E, Gan-Or Z, Orr-Urtreger A, Giladi N.

J Neural Transm (Vienna). 2009 Nov;116(11):1473-82. doi: 10.1007/s00702-009-0303-0. Review.

PMID:
19756366
3.

Clinical features of LRRK2 parkinsonism.

Haugarvoll K, Wszolek ZK.

Parkinsonism Relat Disord. 2009 Dec;15 Suppl 3:S205-8. doi: 10.1016/S1353-8020(09)70815-6. Review.

PMID:
20082991
4.

The heterozygous R1441C mutation of leucine-rich repeat kinase 2 gene in a Chinese patient with Parkinson disease: A five-year follow-up and literatures review.

Peng F, Sun YM, Chen C, Luo SS, Li DK, Wang YX, Yang K, Liu FT, Zuo CT, Ding ZT, An Y, Wu JJ, Wang J.

J Neurol Sci. 2017 Feb 15;373:23-26. doi: 10.1016/j.jns.2016.12.009. Epub 2016 Dec 9. Review.

PMID:
28131193
5.

LRRK2 G2019S in the North African population: a review.

Benamer HT, de Silva R.

Eur Neurol. 2010;63(6):321-5. doi: 10.1159/000279653. Epub 2010 Apr 23. Review.

PMID:
20413974
6.

The synaptic function of LRRK2.

Lee S, Imai Y, Gehrke S, Liu S, Lu B.

Biochem Soc Trans. 2012 Oct;40(5):1047-51. Review.

PMID:
22988863
7.

[Molecular mechanisms of LRRK2-mediated abnormal phosphorylation of Tau protein].

Kawakami F, Ichikawa T.

Seikagaku. 2016 Apr;88(2):248-52. Review. Japanese. No abstract available.

PMID:
27192882

Supplemental Content

Support Center